{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-25-000216","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.180595+00:00","generated_at":"2026-05-17T20:07:37.976952+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"KORU Medical Q2 revenue up 21% to record $10.2M; raises FY 2025 revenue guidance","bullets":["Q2 2025 net revenue of $10.2 million, +21% YoY; Core revenue $9.3M (+19%), PST $0.9M (+42%).","Adjusted EBITDA positive $0.3M vs ($0.4M) in prior year; net loss narrowed to $0.2M from $1.3M.","Raises FY 2025 revenue guidance to $39.5-$40.5M (prev. $38.5-$39.5M); gross margin guidance 61%-63% reaffirmed.","Cash balance $8.1M at Q2-end; reiterated positive operating cash flow for FY 2025.","Adam Kalbermatten named Chief Commercial Officer; FDA 510(k) submitted for a rare disease biologic drug."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-25-000216","json":"https://secwatch.observer/filing/0001161697-25-000216.json","markdown":"https://secwatch.observer/filing/0001161697-25-000216.md","text":"https://secwatch.observer/filing/0001161697-25-000216.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169725000216/0001161697-25-000216-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169725000216/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:07:37.976952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}